Clinical Trials Directory

Trials / Completed

CompletedNCT01922505

Eradication Rates of Helicobacter Pylori and Its Affecting Factors

The Trend of Eradication Rates of First-line Triple Therapy for Helicobacter Pylori and Clinical Factors That Affect the Eradication in Korean: Single Center Experience for Recent Ten Years

Status
Completed
Phase
Study type
Observational
Enrollment
2,500 (actual)
Sponsor
Seoul National University Bundang Hospital · Academic / Other
Sex
All
Age
16 Years – 92 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to investigate the trend of eradication rates of first-line triple therapy for Helicobacter pylori in recent ten years and clinical factors that affect the eradication in Korean.

Detailed description

A PPI triple regimen combining a proton pump inhibitor(PPI) with two antibiotics (amoxicillin and clarithromycin) is currently considered the gold standard therapy for eradication of H. pylori. However, recently the eradication rate with first-line treatment has a tendency to decrease because of increasing antibiotics resistance. In addition, PPI is mainly metabolized by cytochrome p450 2C19 (CYP2C19) in the liver and several reports have suggested that differences in th CYP2C19 genotype are associated with H. pylori eradication failure. Thus, the first aim of this study is to investigate the trend of eradication rates of first-line triple therapy in recent ten years. And the second aim is to analyze the antibiotics resistance rate for H. pylori by using culture minimal inhibitory concentrations(MICs) result and to analyze the association between CYP2C19 genotype and eradication rate of H.pylori. And also investigate the other clinical factors (age, gender, underlying disease, cigarette smoking and alcohol use) that affect the eradication rate.

Conditions

Interventions

TypeNameDescription
DRUGPPI triple therapy

Timeline

Start date
2003-01-01
Primary completion
2013-05-01
Completion
2013-05-01
First posted
2013-08-14
Last updated
2013-08-14

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT01922505. Inclusion in this directory is not an endorsement.